Dihydrotriazine compound and composition for use in podology, in the prophylaxis and / or treatment of foot disorders, the treatment of tattoos and / or tattoo wounds and the treatment of a piercing and / or piercing wounds

Abstract

The invention relates to a dihydrotriazine compound and a composition for use – in medical or nonmedical foot care and / or - in the prophylaxis and / or treatment of foot disorders and / or – in the treatment, in particular disinfection, of tattoos and / or tattoo wounds and / or - in the treatment, in particular disinfection, of a piercing and / or piercing wounds and / or – in the prophylaxis and / or treatment of inflamed tattoo wounds and / or piercing wounds.

Description

[0001] Dihydrotriazine compound and composition for use in podiatry, in the prophylaxis and / or treatment of foot diseases, the treatment of tattoos and / or tattoo wounds and the treatment of piercings and / or piercing wounds

[0002] FIELD OF APPLICATION AND STATE OF THE ART

[0003] The invention relates to a dihydrotriazine compound and a composition for use in podiatry, ie in medical or non-medical foot care, and / or in the prophylaxis and / or treatment of foot diseases and / or in the treatment, in particular disinfection, of tattoos and / or tattoo wounds and / or in the treatment, in particular disinfection, of a piercing and / or piercing wounds and / or in the prophylaxis and / or treatment of inflamed tattoo wounds and / or piercing wounds.

[0004] Tattooing causes superficial damage and partial severing of the skin. Some facial and tongue piercings also sever the mucous membrane. This creates entry points for microorganisms that can cause painful infections.

[0005] Preventing infections also plays an important role in foot care.

[0006] Aqueous and alcohol-based compositions are known that can be used to reduce bacteria and fungi on intact, injured, especially severed, or damaged skin, as well as on mucous membranes. For example, chlorhexidine in the form of its gluconate or acetate salt has been used topically in a variety of products for more than 60 years. However, this compound has the fundamental disadvantage of limited stability and, upon prolonged storage, strong heat, or exposure to light, forms toxic by-products and degradation products. Furthermore, chlorhexidine's effectiveness against fungi and yeasts is only weak.

[0007] It is also known that polyhexamethylene biguanide (polihexanide) can be used for the treatment of wounds, on the skin, and as a preservative in cosmetic preparations. Polyhexamethylene biguanide is an oligomer composed of several individual substances. Analytical characterization is therefore not trivial. In the case of polyhexamethylene biguanide, too, its effectiveness against fungi, including yeasts, is only weakly pronounced—similar to chlorhexidine. A composition containing polyhexamethylene biguanide and a surfactant that can be used for the treatment of wounds is known, for example, from EP 1 404 311 B1.

[0008] Triclosan is also known to be used as an antimicrobial substance in topical preparations, such as hand sanitizers and wash preparations. However, there are now concerns regarding its external application.

[0009] Octenidine hydrochloride has established itself as a cationic active ingredient for antiseptic solutions and gels for application to the skin, mucous membranes, and wounds. Corresponding formulations are commercially available under the names "Octenisept" and "Octenilin." However, octenidine also has the disadvantage of being relatively weakly effective against fungi and yeasts. Furthermore, its relatively high cytotoxicity and moderate tolerability limit its use in products with long-term contact with living tissue.

[0010] Novel dihydrotriazine compounds are known from EP 1 574 503 A1. In particular, it is described that the compounds can be used for the production of various dosage forms, for example, tablets, pills, capsules, powders, granules, suppositories, injections, pastes, ointments, creams, gels, gel-like creams, lotions, emulsions, suspensions, poultices, plasters, liniments, aerosols, syrups, oral preparations, eye drops, and nasal drops for the treatment and prevention of bacterial infectious diseases, as well as for disinfection and sterilization.

[0011] WO 2020 / 108880 A1 discloses a composition for the treatment of mucous membranes and wounds. In addition to femotaxidine, the composition contains a defoamer.

[0012] WO 2020 / 108881 A1 discloses a composition for the treatment of mucous membranes and wounds which contains a surfactant in addition to femotaxidine.

[0013] There is still a need for antimicrobial compositions

[0014] TASK AND SOLUTION

[0015] The object of the invention is to provide a compound and composition which can be used for the treatment of tattoos and piercings as well as in podiatry and in particular at least partially avoid the disadvantages described in connection with compositions known from the prior art.

[0016] This object is achieved according to the invention by a dihydrotriazine compound having the features of independent claim 1 and by a composition according to claim 8. Preferred embodiments of the dihydrotriazine compound and composition are the subject of the dependent claims and the description. The wording of all claims is hereby incorporated into the description by express reference.

[0017] According to a first aspect, the invention relates to a dihydrotriazine compound of the following general formula I:

[0018] Formula I where

[0019] R-, (i) a phenyl group or a phenylalkyl group, each of which is optionally substituted by 1 to 3 substituents selected from the group consisting of C 1-6 alkoxy group, hydroxy group, a halogen atom, C 1-6 haloalkyl group, C 1-6 alkyl group, a sulfonamido group and C 1-6 haloalkoxy group, (ii) a naphthyl group or a naphthylalkyl group, (iii) a heterocyclic group, a heterocyclic alkyl group or a heterocyclic aminoalkyl group, (iv) an alkyl group having 1 to 16 carbon atoms or (v) a cycloalkyl group or a cycloalkylalkyl group, a hydrogen atom bonded to the nitrogen atom at position 1 or 3 of the dihydrotriazine ring, R2 and R3 independently represent a hydrogen atom or a methyl group,

[0020] R4 represents an alkyl group having 7 to 16 carbon atoms and the dashed line indicates that the position of a double bond is either between positions 1 and 2 or between positions 2 and 3 of the dihydrotriazine ring, or a tautomer thereof or a salt thereof for use in podiatry, ie in medical or non-medical, in particular cosmetic, foot care, and / or in the prophylaxis and / or treatment of foot diseases and / or in the treatment, in particular disinfection, of tattoos and / or tattoo wounds and / or in the treatment, in particular disinfection, of a piercing and / or piercing wounds and / or in the prophylaxis and / or treatment of inflamed tattoo wounds and / or piercing wounds.

[0021] The term “dihydrotriazine compound” is understood in the context of the present invention to mean a compound with a six-membered triazine ring having only two double bonds, i.e. a so-called dihydrotriazine ring, wherein the triazine ring or dihydrotriazine ring has a ring nitrogen atom at positions 1, 3 and 5 and a ring carbon atom at positions 2, 4 and 6, and wherein the position of one double bond is between positions 4 and 5 of the triazine or dihydrotriazine ring and the position of the other, i.e. second or remaining, double bond is either between positions 1 and 2 or between positions 2 and 3 of the triazine ring or dihydrotriazine ring.

[0022] For the purposes of the present invention, the term "fungi" can refer to unicellular or multicellular fungi. For the purposes of the present invention, the term "yeasts" refers to unicellular fungi that reproduce by budding or division (so-called yeasts).

[0023] For the purposes of the present invention, the term “phenyl group” is understood to mean a benzene residue, i.e. the atomic group -C6H5.

[0024] For the purposes of the present invention, the term “benzyl group” is understood to mean the phenylmethyl group -CH2-C6H5, formerly also referred to as a-tolyl group.

[0025] For the purposes of the present invention, the term "phenylalkyl group" means a group in which a linear, i.e., unbranched, or branched alkyl group or alkylene group, in particular having 1 to 6 carbon atoms, is bonded to a phenyl group. The alkyl group or alkylene group can be a substituted or unsubstituted alkyl group or alkylene group. The phenylalkyl group is preferably a benzyl group, methylbenzyl group, such as, in particular, 4-methylbenzyl group, 1-phenylethyl group, 2-phenylethyl group, 1-phenylpropyl group, 2-phenylpropyl group, or 3-phenylpropyl group.

[0026] A benzene ring of the phenyl group or phenylalkyl group may have one to three substituents, in particular selected from the group consisting of halogen atom, hydroxy group, C^-alkyl group, O-, C-haloalkyl group, O-, C-haloalkoxy group, C-, C-haloalkoxy group and sulfonamido group.

[0027] The term “halogen atom” in the context of the present invention may mean a fluorine atom, a chlorine atom, a bromine atom or an iodine atom.

[0028] The term "C^-alkyl group" can, for the purposes of the present invention, mean a corresponding linear or branched alkyl group, i.e., a group having 1 to 6 carbon atoms. The alkyl group can be a substituted or unsubstituted alkyl group. For example, the C^-alkyl group can be a methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, isobutyl group, sec-butyl group, tert-butyl group, n-pentyl group, sec-pentyl group, isopentyl group, neopentyl group, n-hexyl group, or isohexyl group. The term "C^-haloalkyl group" can, for the purposes of the present invention, mean, in particular, a chloromethyl group, bromomethyl group, 1-chloroethyl group, or trifluoromethyl group.

[0029] The term “C^e-alkoxy group” in the sense of the present invention can mean in particular a methoxy group, ethoxy group, n-propoxy group, isopropoxy group, n-butoxy group or isobutoxy group.

[0030] The term “C^e-haloalkoxy group” in the sense of the present invention can in particular mean a trifluoromethoxy group.

[0031] The term “naphthyl group” in the sense of the present invention can mean a 1-naphthyl group or a 2-naphthyl group.

[0032] For the purposes of the present invention, the term "naphthylalkyl group" means a group in which a linear, i.e., unbranched, or branched alkyl group, in particular having 1 to 6 carbon atoms, is bonded to a naphthyl group. The alkyl group can be a substituted or unsubstituted alkyl group. The naphthylalkyl group is preferably a 1-naphthylmethyl group, 2-naphthylmethyl group, 1-naphthylethyl group, or 2-naphthylethyl group.

[0033] The term “heterocyclic group” in the context of the present invention means a three- to six-membered heterocyclic group which contains one to three atoms selected from the group consisting of nitrogen atom, oxygen atom and sulfur atom, wherein a benzene ring may be fused or condensed to the heterocyclic group. The heterocyclic group may, for example, be a pyridyl group, a pyrazinyl group, a thiazolyl group, a piperidyl group, a piperazyl group, a tetrahydrofuryl group, a thienyl group, a pyrrolyl group, a pyrrolidinyl group, an oxazolyl group, an imidazolyl group, an isooxazolyl group, an isothiazolyl group, a pyrazolyl group, a tetrahydropyranyl group, a 2-oxotetrahydropyranyl group, a pyrimidinyl group, a pyradizinyl group, a morpholinyl group, a 1,3,5-triazinyl group, a 1,2,4-triazinyl group, a quinolyl group or an isoquinolyl group.

[0034] In particular, the heterocyclic group in the sense of the present invention can be a 2-pyridyl group, a 3-pyridyl group, a 4-pyridyl group, a 2-furyl group, a 2-thiazolyl group, a 1-piperidyl group, a 1-piperazyl group, a 2-quinolyl group, a 3-quinolyl group, a 4-quinolyl group, a 5-quinolyl group, an 8-quinolyl group, a 1-isoquinolyl group, a 3-isoquinolyl group, a 4-isoquinolyl group or a 5-isoquinolyl group.

[0035] The term "heterocyclic alkyl group" in the context of the present invention means a group in which a linear, i.e. unbranched, or branched alkyl group, in particular having 1 to 6 carbon atoms, is bonded to a heterocyclic group, in particular as defined or described in the previous paragraphs. The alkyl group can be a substituted or unsubstituted alkyl group. The heterocyclic alkyl group is preferably a 2-pyridylmethyl group, 3-pyridylmethyl group, 4-

[0036] Pyridylmethyl group, 2-pyridylethyl group, 3-pyridylethyl group, 4-pyridylethyl group,

[0037] Pyrazinylmethyl group, pyrazinylethyl group, 2-furylmethyl group, 2-furylethyl group, 2-

[0038] Thiazolylmethyl group, 2-thiazolylethyl group, 4-piperidylmethyl group, 2-

[0039] Quinolylmethyl group, 3-quinolylmethyl group, 4-quinolylmethyl group, 5-

[0040] Quinolylmethyl group, 8-quinolylmethyl group, 1-isoquinolylmethyl group 3-

[0041] Isoquinolylmethyl group, 4-isoquinolylmethyl group or 5-isoquinolylmethyl group.

[0042] For the purposes of the present invention, the term "heterocyclic aminoalkyl group" means a group in which a linear, i.e., unbranched, or branched alkyl group, in particular having 1 to 12 carbon atoms, is bonded to a heterocyclic amino group. The alkyl group can be a substituted or unsubstituted alkyl group. The heterocyclic aminoalkyl group is preferably a 4-amino-dihydro-1,3,5-triazin-2-ylamino group, a 4-alkylamino-dihydro-1,3,5-triazin-2-ylamino group, or a 4-phenylalkylamino-dihydro-1,3,5-triazin-2-ylamino group.

[0043] The term "alkyl group having 1 to 16 carbon atoms" means, for the purposes of the present invention, a linear, i.e., unbranched, or branched alkyl group having 1 to 16 carbon atoms. The alkyl group can be a substituted or unsubstituted alkyl group. The alkyl group having 1 to 16 carbon atoms is preferably a methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, isobutyl group, sec-butyl group, tert-butyl group, n-hexyl group, n-heptyl group, n-octyl group, tert-octyl group, n-nonyl group, n-decyl group, n-undecyl group, n-dodecyl group, n-tridecyl group, n-tetradecyl group, n-pentadecyl group, or n-hexadecyl group.

[0044] For the purposes of the present invention, the term "cycloalkyl group" refers in particular to a cycloalkyl group having 3 to 6 carbon atoms. For example, the cycloalkyl group can be a cyclopropyl group, cyclobutyl group, cyclopentyl group, or cyclohexyl group.

[0045] For the purposes of the present invention, the term "cycloalkylalkyl group" means, in particular, a group in which a linear, i.e., unbranched, or branched alkyl group, in particular having 1 to 6 carbon atoms, is bonded to a cycloalkyl group, in particular as defined or described in the previous paragraph. The alkyl group can be a substituted or unsubstituted alkyl group. The cycloalkylalkyl group is preferably a cyclohexylmethyl group, a 1-cyclohexylethyl group, or a 2-cyclohexylethyl group.

[0046] For the purposes of the present invention, the term "alkyl group having 7 to 16 carbon atoms" means a linear, i.e., unbranched, or branched alkyl group having 7 to 16 carbon atoms. The alkyl group can be a substituted or unsubstituted alkyl group. The alkyl group having 7 to 16 carbon atoms is preferably an n-heptyl group, n-octyl group, tert-octyl group, n-nonyl group, n-decyl group, n-undecyl group, n-dodecyl group, n-tridecyl group, n-tetradecyl group, n-pentadecyl group, or n-hexadecyl group.

[0047] The term “salt” used in connection with the dihydrotriazine compound of the general formula I can, in the sense of the present invention, mean in particular a salt with an organic acid, such as formic acid, acetic acid, propionic acid, lactic acid, butyric acid, isobutyric acid, malic acid, maleic acid, malonic acid, fumaric acid, succinic acid, succinic acid monoamide, glutaric acid, tartaric acid, oxalic acid, citric acid, glycolic acid, glucuronic acid, ascorbic acid, aspartic acid, glutamic acid, benzoic acid, phthalic acid, salicylic acid, anthranilic acid, benzenesulfonic acid, p-toluenesulfonic acid or methanesulfonic acid.

[0048] For the purposes of the present invention, the term “tattoo” is to be understood as a motif that has been introduced into the skin using ink, pigment or other coloring agents.

[0049] For the purposes of the present invention, the term "tattoo wounds" refers to wounds, particularly in the form of (needle) pricks, created when the aforementioned motif is inserted into the skin. For the purposes of the present invention, the term "piercing" refers to a form of body modification, i.e., a change to the human body, in which jewelry, particularly in the form of rings or bars, is applied to various parts of the human body through the skin and underlying fat and / or cartilage tissue.

[0050] For the purposes of the present invention, the term “piercing wounds” refers to wounds that occur when a piercing is applied to corresponding parts of the human body.

[0051] The present invention is based on the surprising discovery that dihydrotriazine compounds of the general formula I, a tautomer thereof, a salt thereof or a composition comprising such a compound or such a salt can be successfully used in podiatry, in the prophylaxis and / or treatment of foot diseases, in the treatment, in particular disinfection, of tattoos and / or tattoo wounds, in the treatment, in particular disinfection, of a piercing and / or piercing wounds and in the prophylaxis and / or treatment of inflammatory tattoo wounds and / or inflammatory piercing wounds. It is particularly advantageous that the dihydrotriazine compounds orCompositions containing such dihydrotriazine compounds exhibit good efficacy against bacteria and fungi, including yeasts, as well as good tolerance to living tissue, making them particularly suitable for use on skin, mucous membranes, and wounds. It has also been found that, particularly during prolonged contact, no mimic reactions, for example, due to toxic degradation or byproducts, occur.

[0052] In the embodiment of the invention,

[0053] R-, a phenyl group or a phenylalkyl group, each of which is optionally substituted by 1 to 3 substituents selected from the group consisting of fluorine atom, chlorine atom, hydroxy group, methyl group, tert-butyl group, trifluoromethyl group and methoxy group,

[0054] R^ is a hydrogen atom bonded to the nitrogen atom at position 1 or 3 of the dihydrotriazine ring,

[0055] R2 and R3 each represent a methyl group and

[0056] R4an n-octyl group, n-nonyl group or n-decyl group.

[0057] Preferably, R- represents a phenyl group, a benzyl group or a 2-phenylethyl group, each of which is optionally substituted by 1 to 3 substituents selected from the group consisting of fluorine atom, chlorine atom, hydroxy group, methyl group, tert-butyl group, trifluoromethyl group and methoxy group, a hydrogen atom bonded to the nitrogen atom at position 1 or 3 of the dihydrotriazine ring,

[0058] R2 and R3 each represent a methyl group and

[0059] R4an n-octyl group, n-nonyl group or n-decyl group.

[0060] Particularly preferred means / means

[0061] R-, a benzyl group which is optionally substituted by 1 to 3 substituents selected from the group consisting of fluorine atom, chlorine atom, hydroxy group, methyl group, tert-butyl group, trifluoromethyl group and methoxy group, preferably by 1 to 3 methyl groups, particularly preferably by a methyl group,

[0062] R^ is a hydrogen atom bonded to the nitrogen atom at position 1 or 3 of the dihydrotriazine ring,

[0063] R2 and R3 each represent a methyl group and

[0064] R4an n-octyl group, n-nonyl group or n-decyl group.

[0065] In a further embodiment of the invention,

[0066] R-, a phenyl group, 4-chlorophenyl group, 2,4-difluorophenyl group, 2,3,4-trifluorophenyl group, 4-tert-butylphenyl group, 4-methoxyphenyl group, 2-methoxy-4-tert-butylphenyl group, 4-trifluoromethoxyphenyl group, benzyl group, methylbenzyl group such as in particular 4-methylbenzyl group, 4-methoxybenzyl group, 3,4-dimethoxybenzyl group, 4-hydroxybenzyl group, 3,4-dichlorobenzyl group, 2,3,4-trichlorobenzyl group, 4-trifluoromethylbenzyl group, 1-phenylethyl group, 2-phenylethyl group, 1-phenylpropyl group, 2-phenylpropyl group or 3-phenylpropyl group, preferably a methylbenzyl group, particularly preferably a 4-methylbenzyl group,

[0067] R^ is a hydrogen atom bonded to the nitrogen atom at position 1 or 3 of the dihydrotriazine ring,

[0068] R2 and R3 each represent a methyl group and

[0069] R4an n-octyl group, n-nonyl group or n-decyl group.

[0070] In a further embodiment of the invention, R- represents a methylbenzyl group, preferably a 4-methylbenzyl group, and / or R2 and R3 each represent a methyl group and / or R4 represents an n-octyl group. Preferably, R- represents a methylbenzyl group, preferably a 4-methylbenzyl group, R2 and R3 each represent a methyl group, and R4 represents an n-octyl group.

[0071] In a further embodiment of the invention, R- means / means a methylbenzyl group, preferably 4-methylbenzyl group, R^ means a hydrogen atom which is bonded to the nitrogen atom at position 1 or 3 of the dihydrotriazine ring, R2 and R3 each means a methyl group and R4 means an n-octyl group.

[0072] The dihydrotriazine compound particularly preferably has the following formula la:

[0073] Alternatively, the dihydrotriazine compound may have the following formula Ib:

[0074] Formula Ib

[0075] In a further embodiment of the invention, the dihydrotriazine compound, the tautomer thereof or the salt thereof is 4-octylamino-1,6-dihydro-6,6-dimethyl-2-(4'-methylbenzylamino)-1,3,5-triazine gluconate, which can also be referred to as 6,6-dimethyl-N2-(4-methylbenzyl)-N4-octyl-1,6-dihydro-[1,3,5]triazine-2,4-diamine gluconate. Preferably, the dihydrotriazine compound, tautomer thereof, or salt thereof is 4-octylamino-1,6-dihydro-6,6-dimethyl-2-(4'-methylbenzylamino)-1,3,5-triazine-D-gluconate, which may also be referred to as 6,6-dimethyl-N2-(4-methylbenzyl)-N4-octyl-1,6-dihydro-[1,3,5]triazine-2,4-diamine-D-gluconate. The dihydrotriazine compound or dihydrotriazine compound salt disclosed in this paragraph has been found to be particularly effective in achieving the advantages of the invention.

[0076] The dihydrotriazine compound or the dihydrotriazine compound salt 4-octylamino-1,6-dihydro-6,6-dimethyl-2-(4'-methylbenzylamino)-1,3,5-triazine-D-gluconate mentioned in the previous paragraph is commercially available under the name “Femotaxidin” and can be represented by the following formula la # be shown:

[0077] Formula la #

[0078] In a further embodiment of the invention, the dihydrotriazine compound, the tautomer thereof or the salt thereof is 4-octylamino-3,6-dihydro-6,6-dimethyl-2-(4'-methylbenzylamino)-1,3,5-triazine gluconate, in particular 4-octylamino-3,6-dihydro-6,6-dimethyl-2-(4'-methylbenzylamino)-1,3,5-triazine-D-gluconate.

[0079] In a further embodiment of the invention, the foot diseases are selected from the group consisting of diabetic foot syndrome, athlete's foot, foot eczema such as dyshidrotic foot eczema, nail fungus, paronychia, hyperkeratosis, blisters, warts, wounds, open and / or inflamed wounds and skin abrasions.

[0080] According to a second aspect, the invention relates to a composition for application or use in podiatry, ie in medical or non-medical, in particular cosmetic, foot care, and / or in the prophylaxis and / or treatment of foot diseases and / or in the treatment, in particular disinfection, of tattoos and / or tattoo wounds and / or in the treatment, in particular disinfection, of a piercing and / or piercing wounds and / or in the prophylaxis and / or treatment of inflamed tattoo wounds and / or piercing wounds.

[0081] The composition is characterized in that it comprises a dihydrotriazine compound according to the first aspect of the invention or a tautomer thereof or a salt thereof.

[0082] In principle, the composition can be in the form of a solution (such as an aqueous solution), a suspension (such as an aqueous suspension), an emulsion (such as an aqueous emulsion), tablets, pills, capsules, a powder, granules, a suppository, an injection, a paste, an ointment, a cream, a gel (such as hydrogels), a gel-like cream, a lotion, a syrup or an aerosol.

[0083] The composition is preferably in the form of an aqueous, i.e., water-containing, composition. In particular, the composition may be in the form of a solution, in particular an aqueous solution, or a gel, in particular a hydrogel.

[0084] The concentration of the dihydrotriazine compound, the tautomer thereof or the salt thereof is preferably selected such that the composition has an antimicrobial activity against bacteria, in particular against gram-positive bacteria and / or against gram-negative bacteria, preferably against both gram-positive bacteria and gram-negative bacteria.

[0085] The dihydrotriazine compound, its tautomer, or its salt preferably has a proportion of 0.001 wt.% to 0.5 wt.%, in particular 0.01 wt.% to 0.2 wt.%, preferably 0.05 wt.% to 0.15 wt.%, based on the total weight of the composition. In the case of the aforementioned proportions, the antimicrobial properties and, in particular, the good compatibility of the dihydrotriazine compound, its tautomer, or its salt are particularly effective. In a further embodiment of the invention, the composition further comprises a surface-active compound.

[0086] For the purposes of the present invention, the term "surface-active compound" is understood to mean a compound that, through its presence in a liquid, in particular in water or an aqueous liquid, changes its surface tension and / or interfacial tension, in particular between two phases. The surface-active compound for the purposes of the present invention can, in particular, be a surfactant.

[0087] The surface-active compound can be selected from the group consisting of non-ionic surface-active compound, cationic surface-active compound, zwitterionic surface-active compound and combinations, in particular mixtures, of at least two of the aforementioned surface-active compounds.

[0088] For the purposes of the present invention, the term “nonionic surface-active compound” refers to a surface-active compound which does not contain any dissociable functional groups and therefore does not separate into ions in water or an aqueous liquid.

[0089] For the purposes of the present invention, the term “zwitterionic surface-active compound” refers to a compound which has both a negatively and a positively charged functional group (so-called amphoteric surface-active compound).

[0090] For the purposes of the present invention, the term “cationic surface-active compound” is to be understood as meaning a surface-active compound which has a positively charged functional group but not an additional negatively charged group.

[0091] A non-ionic or zwitterionic surfactant compound has the particular advantage that there are no or few interactions with the dihydrotriazine compound and that it is also very well tolerated by skin, mucous membranes and wounds.

[0092] The nonionic surfactant is preferably selected from the group consisting of poloxamer, fatty alcohol alkoxylate such as fatty alcohol ethoxylate, polyvinylpyrrolidone, alkyl polyglucoside, and combinations, in particular mixtures, of at least two of the aforementioned nonionic surfactants. The nonionic surfactants mentioned in this paragraph and described in more detail below have proven particularly suitable for reducing or avoiding the adverse irritation potential of the dihydrotriazine compound, its tautomer, or its salt, from a wound therapy perspective.

[0093] For the purposes of the present invention, the term “poloxamer” is understood to mean a block copolymer of ethylene oxide and propylene oxide (so-called EO / PO block copolymers).

[0094] The poloxamer preferably has 2 to 130 structural units -CH2-CH2-O- and / or 15 to 67 structural units -CHCH3-CH2-O- per molecule.

[0095] The poloxamer may in particular be poloxamer 407, poloxamer 188 or a combination, in particular a mixture, thereof.

[0096] The use of a poloxamer as a surface-active compound may be particularly preferred according to the invention, since poloxamers, in addition to surface-active properties, also possess foam-suppressing or foam-reducing properties and / or emulsifying properties. This allows foam formation attributable to the dihydrotriazine compound, its tautomer, or its salt to be particularly advantageously dampened, mitigated, or suppressed.

[0097] The use of polyvinylpyrrolidone as a surface-active compound may also be particularly preferred according to the invention, since this compound possesses emulsifying properties in addition to its surface-active properties. The advantages mentioned in the previous paragraph apply accordingly. In addition, the use of polyvinylpyrrolidone has the advantage that it can bind water and thus act as a viscosity regulator.

[0098] For the purposes of the present invention, the term "fatty alcohol alkoxylate" is understood to mean a non-ionic surface-active compound whose lipophilic moiety comprises a fatty alcohol, consists of a fatty alcohol, or is derived from a fatty alcohol, and whose hydrophilic moiety comprises a polyalkylene glycol, in particular a short- or medium-chain polyalkylene glycol, or consists of a polyalkylene glycol, in particular a short- or medium-chain polyalkylene glycol, or is derived from a polyalkylene glycol, in particular a short- or medium-chain polyalkylene glycol. The fatty alcohol and the polyalkylene glycol can, independently of one another, have 8 to 22 carbon atoms. The fatty alcohol can, in particular, be an alcohol derived from caprylic, capric, lauric, palmitic, stearic, or oleic acid, or from branched isononyl, isundecyl, isotridecyl, isopentadecyl, or isononadecyl alcohols.In the context of the present invention, the fatty alcohol alkoxylate can also be referred to as polyalkylene glycol ether.

[0099] As already mentioned, the fatty alcohol alkoxylate can in particular be a fatty alcohol ethoxylate.

[0100] The fatty alcohol ethoxylate is preferably a polyoxyethylene ether of lauryl alcohol, a polyoxyethylene ether of myristyl alcohol, a polyoxyethylene ether of cetyl alcohol, a polyoxyethylene ether of cetylstearyl alcohol, a polyoxyethylene ether of stearyl alcohol, a polyoxyethylene ether of oleyl alcohol, a polyoxyethylene ether of isononane alcohol, a polyoxyethylene ether of isoundecane alcohol, a polyoxyethylene ether of isotridecane alcohol, a polyoxyethylene ether of isopentadecane alcohol, a polyoxyethylene ether of isoheptadecane alcohol, a polyoxyethylene ether of isononadecane alcohol or a combination, in particular a mixture, of at least two of the aforementioned polyoxyethylene ethers.

[0101] The fatty alcohol ethoxylate can in particular be selected from the group consisting of polyoxyethylene (4) lauryl ether, polyoxyethylene (7) lauryl ether, polyoxyethylene (9) lauryl ether, polyoxyethylene (23) lauryl ether, polyoxyethylene (2) cetyl ether, polyoxyethylene (10) cetyl ether, polyoxyethylene (20) cetyl ether, polyoxyethylene (6) cetyl stearyl ether, polyoxyethylene (20) cetyl stearyl ether, polyoxyethylene (25) cetyl stearyl ether, polyoxyethylene (2) stearyl ether, polyoxyethylene (10) stearyl ether, polyoxyethylene (20) stearyl ether, polyoxyethylene (2) oleyl ether, polyoxyethylene (10) oleyl ether, polyoxyethylene (20) oleyl ether, polyoxyethylene (10) monodecyl ether, Polyoxyethylene (10) tridecyl ether and combinations, in particular mixtures, of at least two of the aforementioned fatty alcohol ethoxylates.

[0102] In other words, the fatty alcohol ethoxylate can in particular be selected from the group consisting of Laureth-4, Laureth-7, Laureth-9, Laureth-23, Ceteth-2, Ceteth-10, Ceteth-20, Ceteareth-6, Ceteareth-20, Ceteareth-25, Steareth-2, Steareth-10, Steareth-20, Oleth-2, Oleth-10, Oleth-20, Deceth-10, Trideceth-10 and combinations, in particular mixtures, of at least two of the aforementioned fatty alcohol ethoxylates.

[0103] Fatty alcohol alkoxylates, especially fatty alcohol ethoxylates, have the advantage that they not only have surface-active properties but also act as emulsifiers. For the purposes of the present invention, the term "alkyl polyglucoside" refers to a nonionic sugar surfactant that contains one or more glucose units and an alkyl radical, particularly a long-chain alkyl radical, or consists of one or more glucose units and an alkyl radical, particularly a long-chain alkyl radical. The glucose unit(s) act as the hydrophilic component, while the alkyl radical represents the hydrophobic group.

[0104] The alkyl polyglucoside preferably has 1 to 5 glucose building blocks and / or an alkyl radical having 6 carbon atoms to 22 carbon atoms, preferably 6 carbon atoms to 20 carbon atoms, in particular 6 carbon atoms to 16 carbon atoms, in particular 8 carbon atoms to 14 carbon atoms.

[0105] The alkyl polyglucoside is preferably a C8 to C2o alkyl polyglucose, in particular C8 to C 16 -Alkylpolyglucose.

[0106] The alkyl polyglucoside is particularly preferably lauryl polyglucose, decyl polyglucose, cocoyl polyglucose, or a combination, in particular a mixture, of at least two of the aforementioned alkyl polyglucosides. The alkyl radical of decyl polyglucose preferably has 8 to 16 carbon atoms, in particular 10 carbon atoms. The alkyl radical of lauryl polyglucose preferably has 12 to 16 carbon atoms, in particular 12 carbon atoms. The alkyl radical of cocoyl polyglucose preferably has 8 to 16 carbon atoms.

[0107] Alkyl polyglucosides also have the advantage that they not only have surface-active properties, but also represent emulsifying compounds.

[0108] The zwitterionic surface-active compound is preferably an alkyl betaine and / or an alkylamidoalkyl betaine, in particular an alkylamidoethyl betaine, alkylamidopropyl betaine or a combination, in particular a mixture, thereof.

[0109] The alkyl betaine may preferably have alkyl groups which independently of one another have 8 carbon atoms to 22 carbon atoms, in particular 8 to 18 carbon atoms.

[0110] The alkylamidoalkylbetaine particularly preferably has at least one fatty acid residue, in particular only one fatty acid residue, (only) two fatty acid residues, or three fatty acid residues. The at least one fatty acid residue preferably has 8 to 22 carbon atoms, in particular 8 to 18 carbon atoms. The fatty acid residue can in particular be a saturated or unsaturated fatty acid residue. The fatty acid residue is preferably a caprylic acid residue, capric acid residue, undecylenic acid residue (undec-10-enoic acid residue), undecylic acid residue (n-undecanoic acid residue), lauric acid residue, stearic acid residue, ricinoleic acid residue, or coconut fatty acid residue.

[0111] Preferably, the alkylamidoalkylbetaine is selected from the group consisting of caprylamidoalkylbetaine, caprimidoalkylbetaine, undecylenamidoalkylbetaine, undecylamidoalkylbetaine, lauramidoalkylbetaine, lauryldimethylaminoacetic acidbetaine, stearinamidoalkylbetaine, ricinolamidoalkylbetaine, cocamidoalkylbetaine and combinations, in particular mixtures, of at least two of the aforementioned alkylamidoalkylbetaines.

[0112] The alkylamidoethyl betaine is preferably an alkylamidoethyl betaine based on a fatty acid, in particular a fatty acid having 8 to 22 carbon atoms, especially 8 to 18 carbon atoms. The fatty acid can be, in particular, a saturated or unsaturated fatty acid. The fatty acid is preferably caprylic acid, capric acid, undecylenic acid (undec-10-enoic acid), undecylic acid (n-undecanoic acid), lauric acid, stearic acid, ricinoleic acid, or coconut fatty acid.

[0113] The alkylamidoethylbetaine is particularly preferably selected from the group consisting of caprylamidoethylbetaine, caprimidoethylbetaine, undecylenamidoethylbetaine, undecylamidoethylbetaine, lauramidoethylbetaine, cocamidoethylbetaine, stearinamidoethylbetaine, ricinolamidoethylbetaine and combinations, in particular mixtures, of at least two of the aforementioned alkylamidoethylbetaines.

[0114] The alkylamidopropyl betaine is preferably an alkylamidopropyl betaine based on a fatty acid, in particular a fatty acid having 8 to 22 carbon atoms, especially 8 to 18 carbon atoms. The fatty acid can be, in particular, a saturated or unsaturated fatty acid. The fatty acid is preferably caprylic acid, capric acid, undecylenic acid (undec-10-enoic acid), undecylic acid (n-undecanoic acid), lauric acid, stearic acid, ricinoleic acid, or coconut fatty acid.

[0115] Particularly preferably, the alkylamidopropyl betaine is selected from the group consisting of caprylamidopropyl betaine, caprimidopropyl betaine, undecylenamidopropyl betaine, undecylamidopropyl betaine, cocamidopropyl betaine, stearinamidopropyl betaine, ricinolamidopropyl betaine and combinations, in particular mixtures, of at least two of the aforementioned alkylamidopropyl betaines.

[0116] The cationic surface-active compound preferably has a saturated or unsaturated organic radical, in particular an alkyl group, having 8 to 22 carbon atoms.

[0117] The cationic surface-active compound can in particular be selected from the group consisting of distearyldimethylammonium chloride, didecyldimethylammonium chloride, cetyltrimethylammonium chloride, cetyltrimethylammonium bromide, cetylpyridinium chloride, mecetronium ethyl sulfate and combinations, in particular mixtures, thereof.

[0118] The surface-active compound preferably has a proportion, in particular active proportion, of 0.001 wt.% to 10 wt.%, in particular 0.01 wt.% to 2 wt.%, preferably 0.1 wt.% to 1 wt.%, based on the total weight of the composition.

[0119] In a further embodiment of the invention, the composition further comprises a complexing agent. Metals or metal ions can be present in raw materials and have a negative impact on the stability of the composition. Particularly if the composition contains unsaturated organic components, e.g., compounds with unsaturated fatty acid residues, metal ions can promote oxidation processes. Complexing agents can bind these undesirable metal ions. Furthermore, complexing agents have the advantage of positively influencing stability against microorganisms.The complexing agent is preferably selected from the group consisting of citric acid, tartaric acid, succinic acid, methylglycine diacetate, ethyldiaminetetraacetate, N,N'-bis-(carboxymethyl)-L-glutamate, polyaspartic acid, iminodisuccinate, phosphonates, phosphonobutanetricarboxylic acid, lauryl alcohol diphosphonic acid, editronic acid, salts of the aforementioned complexing agents and combinations, in particular mixtures, of at least two of the aforementioned complexing agents.

[0120] The complexing agent preferably has a proportion of 0.001 wt.% to 10 wt.%, in particular 0.01 wt.% to 5 wt.%, preferably 0.01 wt.% to 1 wt.%, based on the total weight of the composition.

[0121] In a further embodiment of the invention, the composition further comprises a foam-inhibiting compound or a defoamer. The foam-inhibiting compound or defoamer is preferably a different compound from the surface-active compound. In other words, the foam-inhibiting compound or defoamer and the surface-active compound are selected to be different from one another, ie, they represent different compounds.

[0122] For the purposes of the present invention, the term “foam-inhibiting compound” or “defoamer” is intended to refer to a compound which slows down or attenuates, i.e. mitigates or reduces, or avoids, foam formation, in particular foam formation attributable to the dihydrotriazine compound, the tautomer thereof or the salt thereof.

[0123] The foam-inhibiting compound or defoamer can in particular be selected from the group consisting of alkylamide, silicone, poloxamer and combinations, in particular mixtures, of at least two of the aforementioned foam-inhibiting compounds or defoamers.

[0124] The alkylamide can in particular be an alkylamide of the formula R5-NH-R6, where R5 is n-octyl, iso-octyl, or 2-ethylhexyl and R6 is n- or iso-octane, n- or isononane, or n- or isodecane. According to the invention, the alkylamide can also be a combination, in particular a mixture, of at least two corresponding alkylamides.

[0125] The silicone may be a polydimethylsiloxane, polyether siloxane (siloxane-polyethylene glycol or siloxane-polypropylene glycol), 3D-modified siloxane, also called crosslink siloxane, or a combination, in particular a mixture, of at least two of the aforementioned silicones.

[0126] The poloxamer preferably has 2 to 130 structural units -CH2-CH2-O- and / or 15 to 67 structural units -CHCH3-CH2-O- per molecule.

[0127] In particular, the poloxamer may be poloxamer 407, poloxamer 188 or a combination, in particular a mixture, thereof.

[0128] Particularly preferably, the foam-inhibiting compound or defoamer is selected from the group consisting of N-(2-ethylhexyl)-isononanamide, polydimethylsiloxane, polyether-siloxane such as siloxane-polyethylene glycol or siloxane-polypropylene glycol, 3D-modified siloxane, EO / PO block copolymers, and combinations, in particular mixtures, of at least two of the aforementioned foam-inhibiting compounds or defoamers. A suitable foam-inhibiting compound is commercially available, for example, under the name "Aldo LF."

[0129] Furthermore, the foam-inhibiting compound or defoamer can be a combination, in particular a mixture, of an alkylamide and a silicone. Such a combination is particularly advantageous with regard to suppressing or weakening foam formation of the dihydrazine compound of the general formula I, the tautomer thereof, or the salt thereof. In this case, the alkylamide can have a proportion, in particular active proportion, of 0.0001 wt.% to 0.1 wt.%, in particular 0.0005 wt.% to 0.05 wt.%, preferably 0.001 wt.% to 0.05 wt.%, based on the total weight of the composition, and the silicone can have a proportion, in particular active proportion, of 0.00001 wt.% to 0.01 wt.%, in particular 0.00002 wt.% to 0.005 wt.%, preferably 0.00005 wt.% to 0.005 wt.%, based on the total weight of the composition.

[0130] The foam-inhibiting compound preferably has a proportion of 0.0001 wt.% to 2 wt.%, in particular 0.0005 wt.% to 1.5 wt.%, preferably 0.001 wt.% to 1 wt.%, based on the total weight of the composition.

[0131] In a further embodiment of the invention, the composition further comprises a care substance. The care substance is in particular selected from the group consisting of dexpanthenol, allantoin, alpha-bisabolol, glycerol, sorbitol, urea, mandelic acid, salicylic acid, kojic acid, tranexamic acid, ascorbic acid, ascorbyl glucosides, tocopherol, tocopheryl acetate, lutein, quercetin, ceramides, niacinamide, sodium pyroglutamate, zinc pyroglutamate, zinc gluconate, iron gluconate, iron bisglycinate, carnitine, in particular L-carnitine, betaine, lysine, polylysine, aloe vera, milk proteins such as casein, milk protein hydrolysates such as casein hydrolysates, wheat proteins such as gluten, wheat protein hydrolysates such as gluten hydrolysates, hyaluronic acid, hyaluronic acid hydrolysates, hyaluronic acid derivatives, beta-glucan, menthol, menthyl lactate and combinations, in particular mixtures, of at least two of the the aforementioned care substances.

[0132] The use of the care substance can advantageously keep skin moist and supple. The care substance can be specifically selected depending on the type of application. The use of one or more care substances is particularly advantageous for dry and particularly chapped skin, especially for dry and particularly chapped feet. The care substance preferably has a proportion of 0.001 wt.% to 20 wt.%, in particular 0.01 wt.% to 5 wt.%, preferably 0.05 wt.% to 1 wt.%, based on the total weight of the composition.

[0133] Preferably, the composition comprises the following: a dihydrotriazine compound according to the general formula I or a tautomer thereof or a salt thereof, at least one compound selected from the group consisting of surface-active compound, complexing agent, foam-inhibiting compound and combinations, in particular mixtures, of at least two of the aforementioned compounds, and a conditioning agent.

[0134] With regard to the dihydrotriazine compound, the tautomer thereof or the salt thereof, the surface-active compound, the complexing agent, the antifoam compound and the care substance, reference is made in full to the previous statements.

[0135] The composition preferably also contains water. The water can, in particular, comprise a proportion of 0.1 wt.% to 99.99 wt.%, in particular 10 wt.% to 99.9 wt.%, preferably 80 wt.% to 99.8 wt.%, based on the total weight of the composition. The components of the composition are preferably supplemented with water to 100 wt.%.

[0136] The water is preferably purified water. In particular, the water may be water for injection.

[0137] Alternatively, the composition may further comprise a physiological sodium chloride solution, in particular a 0.9% by weight physiological sodium chloride solution, a Ringer's solution or Ringer's lactate solution.

[0138] In a further embodiment of the invention, the composition further comprises at least one further additive, in particular selected from the group consisting of polymer, solvent, polyalkylene glycol, acid, alkali or base, perfume, aroma, and combinations, in particular mixtures, of at least two of the aforementioned additives. The aforementioned polymer is preferably a polymer for regulating viscosity and / or flow behavior. The polymer can in particular be selected from the group consisting of cellulose, cellulose derivatives, chitosan, chitosan derivatives, chitosan hydrolysates, collagen, collagen derivatives, collagen hydrolysates, polysaccharides, gelatin, partially hydrolyzed gelatin, polyvinylpyrrolidone, and combinations, in particular mixtures, of at least two of the aforementioned polymers.

[0139] The cellulose derivatives can in particular be selected from the group consisting of alkylcellulose, hydroxyalkylcellulose, hydroxyalkylmethylcellulose, hydroxyalkylethylcellulose, carboxymethylcellulose, quaternized hydroxyethylcellulose (polyquaternium-4) and combinations, in particular mixtures, of at least two of the aforementioned cellulose derivatives.

[0140] The polysaccharides can in particular be selected from the group consisting of alginates, agar, locust bean gum, pectin, carrageenan and combinations, in particular mixtures, of at least two of the aforementioned polysaccharides.

[0141] For the purposes of the present invention, the term "carrageenan" refers to a group of long-chain carbohydrates found in red algae cells. These are linear, anionic hydrocolloids that can be differentiated by their chemical structure and exhibit different properties. The various types differ in the proportion of galactose and 3,6-anhydrogalactose, as well as in the number of sulfate groups. In particular, the carrageenan can be selected from the group consisting of K-carrageenan, t-carrageenan, X-carrageenan, and combinations, especially mixtures of at least two of the aforementioned carrageenan types.

[0142] The polymer may have a proportion of 0.001 wt% to 50 wt%, in particular 0.01 wt% to 10 wt%, preferably 0.05 wt% to 5 wt%, based on the total weight of the composition.

[0143] The polyalkylene glycol may in particular be a polyethylene glycol and / or polypropylene glycol, in particular with a molecular mass of 100 to 5,000,000.

[0144] Furthermore, the polyalkylene glycol can have a proportion of 0.001 wt.% to 99 wt.%, in particular 0.01 wt.% to 50 wt.%, preferably 0.1 wt.% to 20 wt.%, based on the total weight of the composition. The solvent can in particular be an organic solvent, preferably selected from the group consisting of alcohol, ketone, ether, ester, and combinations, in particular mixtures of at least two of the aforementioned solvents. The alcohol can be a monohydric alcohol and / or dihydric alcohol and / or trihydric alcohol, in particular having two to ten carbon atoms, preferably two to eight carbon atoms.The alcohol is preferably selected from the group consisting of methanol, ethanol, propan-1-ol, propan-2-ol, propane-1,2-diol, propane-1,3-diol, propane-1,2,3-triol, butane-1,3-diol, pentane-1,2-diol, hexane-1,2-diol, octane-1,2-diol, decane-1,2-diol, hexane-1,2-diol, octane-1,2-diol and combinations, in particular mixtures, of at least two of the aforementioned alcohols. The ketone can in particular have three to eight carbon atoms. For example, the ketone can be butan-2-one. The ether can be, for example, tetrahydrofuran. The ester can in particular be a carbonic acid ester, such as, for example, diethyl carbonate, and / or carboxylic acid esters, such as, for example, ethyl acetate.

[0145] The solvent may have a proportion of 0.001 wt% to 80 wt%, in particular 0.01 wt% to 50 wt%, preferably 0.1 wt% to 20 wt%, based on the total weight of the composition.

[0146] Alternatively, the composition may be free or substantially free of a solvent, in particular organic solvents, preferably an alcohol and / or ketone and / or ether and / or ester. The term "substantially free" in this context means that the composition has a solvent content of < 5 wt.% and > 0 wt.%, in particular < 4 wt.% and > 0 wt.%, preferably < 3 wt.% and > 0 wt.%, in particular < 2 wt.% and > 0 wt.%, in particular < 1 wt.% and > 0 wt.%, based on the total weight of the composition.

[0147] The above-mentioned acid preferably serves to adjust the pH of the composition. The acid can be an inorganic acid, an organic acid, or a mixture thereof. The acid is preferably selected from the group consisting of hydrochloric acid, formic acid, acetic acid, glycolic acid, lactic acid, malic acid, tartaric acid, gluconic acid, gluconodeltalactone, and combinations, in particular mixtures, of at least two of the aforementioned acids. The acid can have a proportion of 0.001 wt.% to 10 wt.%, in particular 0.01 wt.% to 5 wt.%, preferably 0.01 wt.% to 2 wt.%, based on the total weight of the composition.

[0148] The above-mentioned alkali or base preferably serves to adjust the pH of the composition. The alkali or base can be selected from the group consisting of sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, ammonium hydroxide, organic amines, and combinations, especially mixtures, of at least two of the aforementioned alkalis or bases.

[0149] The organic amines can in particular be selected from the group consisting of monoethanolamine, triethanolamine, 2-amino-2-methyl-1-propanol,

[0150] Tetrahydroxypropylethylenediamine, tromethamine, monoisopropanolamine, triisopropanolamine and combinations, especially mixtures, of at least two of the aforementioned organic amines. The alkali or base can have a proportion of 0.001 wt.% to 10 wt.%, especially

[0151] 0.01 wt% to 5 wt%, preferably 0.01 wt% to 2 wt%, based on the total weight of the composition

[0152] As already mentioned, the composition may further comprise a perfume and / or aroma. For the purposes of the present invention, a perfume or aroma is preferably understood to be a liquid, oily, or solid mixture of substances of natural, nature-identical, and / or synthetic origin that influences or alters the odor and / or taste of the composition. The mixtures of substances may contain exclusively components of natural origin, exclusively components of synthetic origin, or components of both natural and synthetic origin.

[0153] The perfume or aroma may have a proportion of 0.001 wt% to 5 wt%, in particular 0.01 wt% to 1 wt%, preferably 0.05 wt% to 0.5 wt%, based on the total weight of the composition.

[0154] Depending on its intended use, the composition may be further manufactured under controlled hygienic conditions or aseptically in a clean room.

[0155] Furthermore, the composition can be in sterilized form. For example, the composition can be sterilized by gamma irradiation, beta sterilization, plasma sterilization, heat sterilization, or sterilization with ethylene oxide. With regard to further features and advantages of the composition, in particular with regard to the dihydrotriazine compound, the tautomer thereof, or the salt thereof, reference is made in full to the statements made in the context of the first aspect of the invention. The embodiments described therein, in particular with regard to the dihydrotriazine compound, the tautomer thereof, or the salt thereof, also apply mutatis mutandis to the composition according to the second aspect of the invention.

[0156] According to a third aspect, the invention relates to the use of a dihydrotriazine compound according to the first aspect of the invention or a tautomer thereof or a salt thereof or a composition according to the second aspect of the invention for non-medical foot care and / or for the treatment, in particular disinfection, of tattoos and / or for the treatment, in particular disinfection, of a piercing.

[0157] With regard to further features and advantages of the use, in particular with regard to the dihydrotriazine compound, the tautomer thereof, or the salt thereof, as well as the composition, reference is made in full to the statements made in the context of the first and second aspects of the invention. The embodiments described therein, in particular with regard to the dihydrotriazine compound, the tautomer thereof, the salt thereof, and the composition, also apply mutatis mutandis to the use according to the third aspect of the invention.

[0158] Further features and advantages of the invention will become apparent from the following description of preferred embodiments. Individual features can be implemented individually or in combination with one another. The described embodiments serve merely to further explain the invention without limiting it thereto.

[0159] EXAMPLE PART

[0160] 1. Aqueous solution for use in podiatry:

[0161] 2. Aqueous solution: 3. Aqueous solution

[0162] 4. Aqueous solution for the treatment of freshly applied tattoos and pierced skin: 5. Aqueous solution for the treatment of feet

[0163] 6. A composition not according to the invention: In this composition, unlike Examples 1 to 5, dilute hydrochloric acid was used for neutralization, since polihexanide is present as hydrochloride and an impairment of the effect by gluconodeltalactone could not be excluded.

[0164] The compositions according to Examples 1 to 6 were tested for efficacy against the yeast Candida albicans according to EN 13624. The compositions according to Examples 1 to 5 showed good efficacy against Candida albicans with exposure times of 1 to 15 minutes. In contrast, the composition according to Example 6 did not show sufficient efficacy against Candida albicans.

[0165] Furthermore, the compositions according to the invention proved to be non-irritating to intact skin. Furthermore, the compositions according to the invention were also found to be well tolerated on scratched and cut skin, as well as on mucous membranes.

Claims

Patent claims 1. Dihydrotriazine compound of the following general formula I Formula I where R-, (i) a phenyl group or a phenylalkyl group, each of which is optionally substituted by 1 to 3 substituents selected from the group consisting of C 1-6 alkoxy group, hydroxy group, a halogen atom, C 1-6 haloalkyl group, C 1-6 alkyl group, a sulfonamido group and C 1-6 haloalkoxy group, (ii) a naphthyl group or a naphthylalkyl group, (iii) a heterocyclic group, a heterocyclic alkyl group or a heterocyclic aminoalkyl group, (iv) an alkyl group having 1 to 16 carbon atoms or (v) a cycloalkyl group or a cycloalkylalkyl group, a hydrogen atom bonded to the nitrogen atom at position 1 or 3 of the dihydrotriazine ring, R2 and R3 independently represent a hydrogen atom or a methyl group, R4 represents an alkyl group having 7 to 16 carbon atoms and the dashed line indicates that the position of a double bond is either between positions 1 and 2 or between positions 2 and 3 of the dihydrotriazine ring, or a tautomer thereof or a salt thereof for use in medical or non-medical foot care and / or the prophylaxis and / or treatment of foot diseases and / or the treatment, in particular disinfection, of tattoos and / or tattoo wounds and / or the treatment, in particular disinfection, of a piercing and / or piercing wounds and / or the prophylaxis and / or treatment of inflamed tattoo wounds and / or piercing wounds.

2. Dihydrotriazine compound for use according to claim 1, characterized in that RT represents a phenyl group or a phenylalkyl group, in particular benzyl group, each of which is optionally substituted by 1 to 3 substituents selected from the group consisting of fluorine atom, chlorine atom, hydroxy group, methyl group, tert-butyl group, trifluoromethyl group and methoxy group, R represents a hydrogen atom bonded to the nitrogen atom at position 1 or 3 of the dihydrotriazine ring, R2 and R3 each represent a methyl group and R4 represents an n-octyl group, n-nonyl group or n-decyl group.

3. Dihydrotriazine compound for use according to claim 1 or 2, characterized in that R-, a phenyl group, 4-chlorophenyl group, 2,4-difluorophenyl group, 2,3,4-trifluorophenyl group, 4-tert-butylphenyl group, 4-methoxyphenyl group, 2-methoxy-4-tert-butylphenyl group, 4- Trifluoromethoxyphenyl group, benzyl group, methylbenzyl group, 4-methylbenzyl group, 4-methoxybenzyl group, 3,4-dimethoxybenzyl group, 4-hydroxybenzyl group, 3,4-dichlorobenzyl group, 2,3,4-trichlorobenzyl group, 4-trifluoromethylbenzyl group, 1-phenylethyl group, 2-phenylethyl group, 1-phenylpropyl group, 2-phenylpropyl group or 3-phenylpropyl group, preferably a 4-methylbenzyl group, R^ represents a hydrogen atom bonded to the nitrogen atom at position 1 or 3 of the dihydrotriazine ring, R2 and R3 each represent a methyl group and R4 represents an n-octyl group, n-nonyl group or n-decyl group.

4. Dihydrotriazine compound for use according to any one of the preceding claims, characterized in that Rj represents a methylbenzyl group, preferably 4-methylbenzyl group, and / or R2 and R3 each represent a methyl group and / or R4 represents an n-octyl group.

5. A dihydrotriazine compound for use according to any one of the preceding claims, characterized in that R- represents a methylbenzyl group, preferably 4-methylbenzyl group, R^ represents a hydrogen atom bonded to the nitrogen atom at position 1 or 3 of the dihydrotriazine ring, R2 and R3 each represent a methyl group and R4 represents an n-octyl group.

6. Dihydrotriazine compound for use according to any one of the preceding claims, characterized in that the dihydrotriazine compound has the following formula Ia: Formula la 7. A dihydrotriazine compound for use according to any one of the preceding claims, characterized in that the dihydrotriazine compound is 4-octylamino-1,6-dihydro-6,6-dimethyl-2-(4'-methylbenzylamino)-1,3,5-triazine gluconate, 4-octylamino-3,6-dihydro-6,6-dimethyl-2-(4'-methylbenzylamino)-1,3,5-triazine gluconate or a tautomer thereof.

8. Composition for use in medical or non-medical foot care and / or the prophylaxis and / or treatment of foot diseases and / or the treatment, in particular disinfection, of tattoos and / or tattoo wounds and / or the treatment, in particular disinfection, of a piercing and / or piercing wounds and / or the prophylaxis and / or treatment of inflamed tattoo wounds and / or piercing wounds, characterized in that the composition comprises a dihydrotriazine compound or a tautomer thereof or a salt thereof according to any one of the preceding claims.

9. Composition for use according to claim 8, characterized in that the composition further comprises a surface-active compound, in particular selected from the group consisting of poloxamer, fatty alcohol alkoxylate, polyvinylpyrrolidone, alkyl polyglucoside, alkyl betaine, alkylamidoalkyl betaine, distearyldimethylammonium chloride, didecyldimethylammonium chloride, cetyltrimethylammonium chloride, cetyltrimethylammonium bromide, cetylpyridinium chloride, mecetronium ethyl sulfate and combinations of at least two of the aforementioned surface-active compounds.

10. Composition for use according to claim 8 or 9, characterized in that the composition further comprises a complexing agent, in particular selected from the group consisting of citric acid, tartaric acid, succinic acid, methylglycine diacetate, ethyldiaminetetraacetate, N,N'-bis-(carboxymethyl)-L-glutamate, polyaspartic acid, iminodisuccinate, Phosphonobutanetricarboxylic acid, editronic acid, salts of the aforementioned complexing agents and combinations of at least two of the aforementioned complexing agents.

11. Composition for use according to one of claims 8 to 10, characterized in that the composition further comprises a foam-inhibiting compound, in particular selected from the group consisting of alkylamide, silicone, poloxamer and combinations of at least two of the aforementioned foam-inhibiting compounds.

12. Composition for use according to one of claims 8 to 11, characterized in that the composition further comprises a care substance, in particular selected from the group consisting of dexpanthenol, allantoin, alpha-bisabolol, glycerol, sorbitol, urea, mandelic acid, salicylic acid, kojic acid, tranexamic acid, ascorbic acid, ascorbyl glucosides, tocopherol, tocopheryl acetate, lutein, quercetin, ceramides, niacinamide, sodium pyroglutamate, zinc pyroglutamate, zinc gluconate, iron gluconate, iron bisglycinate, carnitine, in particular L-carnitine, betaine, lysine, polylysine, aloe vera, milk proteins such as casein, milk protein hydrolysates such as casein hydrolysates, wheat proteins such as gluten, wheat protein hydrolysates such as gluten hydrolysates, hyaluronic acid, hyaluronic acid hydrolysates, Hyaluronic acid derivatives, beta-glucan, menthol, menthyl lactate and combinations of at least two of the aforementioned care ingredients.

13. Composition for use according to one of claims 8 to 12, characterized in that the composition further comprises at least one further additive, in particular selected from the group consisting of polymer, alcohol, polyalkylene glycol, acid, alkali or base, perfume, aroma and combinations of at least two of the aforementioned additives.

14. Composition for use according to one of the preceding claims, characterized in that the foot diseases are selected from the group consisting of diabetic foot syndrome, athlete's foot, foot eczema such as dyshidrotic foot eczema, nail fungus, paronychia, hyperkeratosis, blisters, warts, wounds, open and / or inflamed wounds and skin abrasions.

Images